Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €6.11 EUR
Change Today +0.043 / 0.71%
Volume 0.0
LMW On Other Exchanges
Symbol
Exchange
Frankfurt
As of 4:55 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (LMW) Snapshot

Open
€6.07
Previous Close
€6.07
Day High
€6.18
Day Low
€6.07
52 Week High
01/15/15 - €7.99
52 Week Low
09/2/14 - €3.80
Market Cap
385.3M
Average Volume 10 Days
20.0
EPS TTM
--
Shares Outstanding
63.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENOPORT INC (LMW)

xenoport inc (LMW) Related Businessweek News

No Related Businessweek News Found

xenoport inc (LMW) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase I clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is in Phase III clinical trials used for the treatment of spasticity in multiple sclerosis; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease has completed Phase II clinical trials. The company has a license agreement with Indivior PLC to develop and commercialize pharmaceutical products containing arbaclofen placarbil; license agreement with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan; and collaboration agreement with Glaxo Group Limited to develop and commercialize gabapentin enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

152 Employees
Last Reported Date: 02/27/15
Founded in 1999

xenoport inc (LMW) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $500.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $439.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $364.2K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $346.1K
Compensation as of Fiscal Year 2014.

xenoport inc (LMW) Key Developments

Xenoport, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Xenoport, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenues were $8,621,000 compared to $5,334,000 a year ago. Loss from operations was $23,654,000 compared to $19,333,000 a year ago. Net loss was $24,481,000 compared to $19,387,000 a year ago. Basic and diluted net loss per share was $0.39 compared to $0.31 a year ago. The increase in revenue was principally due to increased HORIZANT net product sales, which totaled $8.2 million for the quarter compared to $4.9 million for the second quarter of 2014. The increase in HORIZANT net product sales was principally due to increased sales volume and to a lesser extent, increased average net selling price. For the six months, the company's total revenues were $15,688,000 compared to $8,709,000 a year ago. Loss from operations was $43,524,000 compared to $39,816,000 a year ago. Net loss was $44,890,000 compared to $39,935,000 a year ago. Basic and diluted net loss per share was $0.71 compared to $0.67 a year ago.

Xenoport, Inc. to Report Q2, 2015 Results on Aug 05, 2015

Xenoport, Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Aug 05, 2015

Xenoport, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Xenoport, Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMW:GR €6.11 EUR +0.043

LMW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $4.64 USD -0.03
Alkermes PLC $59.41 USD -0.15
Bristol-Myers Squibb Co $58.20 USD -1.27
Skyepharma PLC 320.50 GBp -3.25
Valeant Pharmaceuticals International Inc C$296.20 CAD -8.79
View Industry Companies
 

Industry Analysis

LMW

Industry Average

Valuation LMW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit www.xenoport.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.